Watch Our Story in Action
Latest Updates
AbstimX™ enters veterinary clinical study
January 2026
Network Immunology has initiated a study evaluating AbstimX in dogs with atopic dermatitis, conducted independently at an academic veterinary dermatology centre. Dogs naturally develop allergic conditions that share features with human disease, and the study is expected to provide information on safety, immune response and clinical effect.
Japanese patent granted for AbstimX™
June 2025
Network Immunology has been granted a Japanese patent covering AbstimX. With grants now in place in the United States, China and Japan, the platform is protected in three of the four largest pharmaceutical markets. Applications remain pending in additional jurisdictions.
China grants patent for AbstimX™
December 2024
Network Immunology has been granted a Chinese patent covering AbstimX, extending protection of the platform into one of the world's largest pharmaceutical markets.
United States patent granted for AbstimX™
September 2024
The United States Patent and Trademark Office has granted Network Immunology patent US 12,090,202, covering AbstimX for the treatment and prevention of allergic disease. The patent includes a composition claim over the two-component combination and remains in force to December 2041.